Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)

Prevail Therapeutics

Status and phase: Active, not recruiting; Phase 2; Phase 1

Conditions: Gaucher Disease, Type 2

Treatments: Drug: Methylprednisolone; Drug: Prednisone; Drug: Sirolimus; Genetic: LY3884961

Study type: Interventional

Funder types: Industry

Identifiers

NCT04411654

J3Z-MC-OJAB (PRV-GD2-101)

Details and patient eligibility

About

J3Z-MC-OJAB is an open-label, Phase 1/2, multicenter study to evaluate the safety and efficacy of single-dose LY3884961 (formerly PR001) in infants diagnosed with Type 2 Gaucher disease (GD2). For each patient, the study will be approximately 5 years in duration. During the first 12 months after dosing, patients will be evaluated for the effects of LY3884961 on safety, tolerability, immunogenicity, biomarkers, and efficacy. Patients will be followed up for an additional 4 years to monitor safety and changes on selected biomarkers and clinical outcomes.

Enrollment: 7 patients

Sex: All

Ages: Under 24 months old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Bi-allelic GBA1 mutations consistent with a diagnosis of GD2 confirmed by the central laboratory.
• Clinical diagnosis of GD2
• Parent/legal guardian is capable of providing signed informed consent; including compliance with the requirements and restrictions listed in the informed consent form (ICF) in this protocol.
• Patient has a parent/legal guardian able to participate in the study as a source of information on the patient's health status and cognitive and functional abilities (including providing input into the rating scales).

Exclusion criteria

• Significant CNS disease other than GD2 that may be a cause for the patient's symptoms or interfere with study objectives.
• Achieved independent gait.
• Severe peripheral symptoms of GD which, in the opinion of the Investigator, would pose an unacceptable risk to the patient or interfere with the patient's ability to comply with study procedures or interfere with the conduct of the study.
• Concomitant disease, condition, or treatment which, in the opinion of the Investigator, would pose an unacceptable risk to the patient or interfere with the patient's ability to comply with study procedures or interfere with the conduct of the study.
• Use of any substrate reduction therapy (SRT) for GD treatment.
• Use of prohibited medications, herbals, or over-the-counter agents as listed in the protocol.
• Any type of prior gene or cell therapy.
• Use of systemic immunosuppressant or corticosteroid therapy other than protocol-specified immunosuppression.
• Participation in another investigational drug or device study within the past 3 months.
• Brain MRI (magnetic resonance imaging) and MRA (magnetic resonance angiography) showing clinically significant abnormality deemed a contraindication to intracisternal injection.
• Clinically significant laboratory test result abnormalities assessed at screening.
• Contraindications or intolerance to radiographic visualization methods (e.g. MRI, MRA, CT), and intolerance to contrast agents used for MRI or CT scans.
• Contraindications to general anesthesia or sedation.

Other protocol-defined inclusion/exclusion criteria may apply.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

7 participants in 2 patient groups

Low Dose

Experimental group

Treatment:

Genetic: LY3884961

Drug: Sirolimus

Drug: Prednisone

Drug: Methylprednisolone

High Dose

Experimental group

Treatment:

Genetic: LY3884961

Drug: Sirolimus

Drug: Prednisone

Drug: Methylprednisolone